Saturday, 5 September 2026European Markets

INTEROIL EXPL PROD Stock 15.03% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with INTEROIL EXPL PROD (IOX.OL) rising 15.03% to kr0.88 on Monday, following the last session's upward trend. Oslo Børs Benchmark Index_GI rose 0.85% to kr1,293.99, following the last session's downward trend on what was a somewhat bullish trend exchanging session today.

INTEROIL EXPL PROD's last close was kr0.77, 40.61% under its 52-week high of kr1.29.

About INTEROIL EXPL PROD

Interoil Exploration and Production ASA, together with its subsidiaries, operates as an upstream oil exploration and production company. It engages in the acquisition, exploration, development, and operation of oil and natural gas properties. The company's portfolio includes two producing concessions and two exploration concessions in Colombia; and one exploration and seven production concessions in Argentina. Interoil Exploration and Production ASA was incorporated in 2005 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, INTEROIL EXPL PROD has a trailing twelve months EPS of kr-0.32.

More news about INTEROIL EXPL PROD (IOX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com